芪苈强心胶囊联合酒石酸美托洛尔治疗慢性心力衰竭34例评价

Effect and Safety Evaluation of Qili Qiangxin Capsules Combined with Metoprolol Tartrate in the Treatment of 34 Cases of Chronic Heart Failure

目的:探讨芪苈强心胶囊联合酒石酸美托洛尔治疗慢性心力衰竭的效果及安全性。方法:纳入2020年4月至2021年2月井冈山市人民医院接诊的68例患者作为本次的研究对象。按照随机数字表法分为两组,每组34例。对照组采用酒石酸美托洛尔治疗。观察组在对照组基础上联合芪苈强心胶囊治疗。比较两组患者的治疗效果以及治疗前后中医症候积分、心衰相关标志物、血液流变学指标、收缩压、舒张压、心率检测结果的变化情况。结果:观察组患者疗程结束时治疗总有效率高于对照组(P<0.05);两组患者治疗后心悸气短、胸闷喘息、胸胁作痛、下肢水肿等积分均低于同组治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组患者治疗后脑钠肽(BNP)、可溶性生长刺激表达基因2蛋白(sST2)检测结果均低于同组治疗前,且观察组低于对照组(P<0.05);两组患者治疗后血管内皮生长因子(VEGF)检测结果均高于同组治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组患者治疗后全血黏度高切、全血黏度中切、全血黏度低切、红细胞压积、血浆黏度、纤维蛋白原检测结果均低于同组治疗前(P<0.05),且观察组低于对照组(P<0.05);两组患者治疗后收缩压、舒张压、心率检测结果均低于同组治疗前(P<0.05);且观察组低于对照组(P<0.05)。结论:芪苈强心胶囊联合美托洛尔治疗慢性心力衰竭效果显著,能够有效改善患者心衰相关标志物和血液流变学指标,应用价值较高。

Objective:To investigate the effect and safety of qili qiangxin capsules combined with metoprolol tartrate in the treatment of chronic heart failure.Methods:68 patients admitted to Jinggangshan People’s Hospital from April 2020 to February 2021 were included as the research object.According to the random number table method,they were divided into two groups,with 34 cases in each group.The control group was treated with metoprolol tartrate.The observation group was treated with qili qiangxin capsules on the basis of the control group.The therapeutic effects of the two groups were compared,as well as the changes of TCM symptom score,heart failure related markers,hemorheological indexes,systolic blood pressure,diastolic blood pressure and heart rate before and after treatment.Results:The total effective rate of the observation group was higher than that of the control group at the end of the course of treatment,and there was significant difference between the data(P<0.05).After treatment,the scores of palpitation,shortness of breath,chest tightness and wheezing,chest and flank pain and lower limb edema in the two groups were lower than those in the same group before treatment,and the observation group was lower than that in the control group,the difference between the data was statistically significant(P<0.05).The results of brain natriuretic peptide(BNP)and soluble growth stimulating gene 2 protein(sST2)in the two groups after treatment were lower than those in the same group before treatment,and the difference between the data in the observation group was lower than that in the control group(P<0.05).The detection results of vascular endothelial growth factor(VEGF)in the two groups after treatment were higher than those in the same group before treatment,and the observation group was higher than that in the control group(P<0.05),and the difference between the data was statistically significant(P<0.05).After treatment,the results of whole blood viscosity high shear,whole blood viscosity medium shear,whole blood viscosity low shear,hematocrit,plasma viscosity and fibrinogen in the two groups were lower than those in the same group before treatment.The difference between the data was statistically significant(P<0.05),and the observation group was lower than that in the control group(P<0.05).The results of systolic blood pressure,diastolic blood pressure and heart rate in the two groups after treatment were lower than those in the same group before treatment(P<0.05),and the observation group was lower than the control group,and the difference was statistically significant(P<0.05).Conclusion:Qili qiangxin capsules combined with metoprolol tartrate is effective in the treatment of chronic heart failure.It can effectively improve the related markers of heart failure and hemorheological indexes,and has high application value.